Michael Sinclair - 02 Mar 2023 Form 4 Insider Report for OPIANT PHARMACEUTICALS, INC.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 02 Mar 2023
Net transaction value: -$1,803,400
SEC form: 4
Accepted by SEC: 03 Mar 2023, 08:10:52 UTC
Prior SEC filing: 15 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Sinclair

Key filing fact

Michael Sinclair filed Form 4 for OPIANT PHARMACEUTICALS, INC. on 03 Mar 2023.

Key facts

This page summarizes Michael Sinclair's Form 4 filing for OPIANT PHARMACEUTICALS, INC..
6 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 03 Mar 2023, 08:10.

Change

Previous filing in this sequence was filed on 15 Jun 2022.
Current net transaction value: -$1,803,400.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OPNT transaction

Common Stock

Disposed to Issuer

Transaction value: $549,000
Shares: -27,450
Change %: -100%
Price: $20.00
Shares after: 0
Date: 02 Mar 2023
Ownership: Footnote
Footnotes: F1, F2

OPNT transaction

Common Stock, par value $0.001 per share

Disposed to Issuer

Transaction value: $454,400
Shares: -22,720
Change %: -100%
Price: $20.00
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F1

OPNT transaction

Common Stock, par value $0.001 per share

Disposed to Issuer

Transaction value: $800,000
Shares: -40,000
Change %: -100%
Price: $20.00
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OPNT transaction Derivative

Options

Disposed to Issuer

Transaction value: $0
Shares: -100,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Underlying class: Common Stock, par value $0.001 per share
Underlying amount: 100,000
Exercise price: $8.00
Footnotes: F3

OPNT transaction Derivative

Options

Disposed to Issuer

Transaction value: $0
Shares: -250,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Underlying class: Common Stock, par value $0.001 per share
Underlying amount: 250,000
Exercise price: $7.25
Footnotes: F3

OPNT transaction Derivative

Options

Disposed to Issuer

Transaction value: $0
Shares: -75,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Mar 2023
Ownership: Direct
Underlying class: Common Stock, par value $0.001 per share
Underlying amount: 75,000
Exercise price: $6.00
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Michael Sinclair is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").

Footnote F2

27,450 shares held in certificate form indirectly by (i) Proton Therapy USA, a entity owned jointly by Dr. Sinclair and his son (5,000 shares); (ii) one pension fund (10,000 shares); (iii) a second pension fund (2,000 shares); (iv) Clearsearch Ltd., an entity who holds the shares for the benefit of Dr. Sinclair (2,650 shares); and (v) Eastkings Pension Fund, an entity which holds the shares for the benefit of Dr. Sinclair's wife (7,800 shares).

Footnote F3

The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.